Precision Biologics
  • Home
  • Company
    • About Us
    • Contact Us
    • Board
    • Leadership
  • Clinical
    • Pipeline
    • Companion Diagnostics
    • Therapeutics
    • Clinical Trials
  • Science
    • Publications
      • Recent
      • Historical
    • Abstracts
    • Posters
    • Presentations
  • News and Events
Search
  • Home
  • Company
    • About Us
    • Contact Us
    • Board
    • Leadership
  • Clinical
    • Pipeline
    • Companion Diagnostics
    • Therapeutics
    • Clinical Trials
  • Science
    • Publications
      • Recent
      • Historical
    • Abstracts
    • Posters
    • Presentations
  • News and Events
  • Home
  • News and Events
  • News

News

14MarMarch 14, 2023

Dr. Philip M. Arlen gives keynote address on NEO-201 Developments at World Antibody Congress, San Diego, CA, March 20th, 2023

Strattmont Group2023-03-16T12:46:14-04:00

Dr. Philip M. Arlen, President and CEO, Precision Biologics, gives keynote address entitled “Preclinical/Clinical Development...

Facebook Twitter LinkedIn
Read more...
14DecDecember 14, 2022

Precision Biologics Successfully Completes Safety Phase and Begins Enrollment in Phase 2 Trial Combining NEO-201 and Pembrolizumab (Keytruda)

Strattmont Group2022-12-19T12:37:16-05:00

READ ARTICLE

Facebook Twitter LinkedIn
Read more...
01DecDecember 1, 2022

Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201

Strattmont Group2022-12-09T10:58:45-05:00

Precision Biologics, Inc. publishes paper on latest findings of the unique target that NEO-201 recognizes,...

Facebook Twitter LinkedIn
Read more...
09NovNovember 9, 2022

Precision Biologics To Deliver Poster Presentations On Clinical And Scientific Programs At Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Strattmont Group2022-11-09T11:56:05-05:00

BETHESDA, Md.--(BUSINESS WIRE)--Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, will present...

Facebook Twitter LinkedIn
Read more...
09NovNovember 9, 2022

SITC 2022 – Posters will be presented in person at the Boston Convention & Exhibition Center on Thursday, November 10th, 2022

Strattmont Group2022-11-09T11:50:08-05:00

Society for the Immunotherapy of Cancer 2022 Annual Meeting, November 8 – 12, Boston, MA,...

Facebook Twitter LinkedIn
Read more...
04OctOctober 4, 2022

Dr. Philip M. Arlen gives presentation on recent NEO-201 clinical development at Biomarkers & Immuno US, 4th Annual Advances in Immuno-Oncology USA Congress, San Diego, CA, October 4, 2022

Strattmont Group2022-10-12T10:30:45-04:00

Dr. Philip M. Arlen gives presentation “Preclinical/Clinical Development of a Neo-Epitope Targeted Monoclonal Antibody for...

Facebook Twitter LinkedIn
Read more...
05JunJune 5, 2022

Precision Biologics, Inc. and National Cancer Institute Collaborators Deliver Poster Presentation at the ASCO Annual Meeting June 5, 2022

Strattmont Group2022-06-03T11:11:01-04:00

Precision Biologics, Inc. and our collaborators at the NCI deliver a poster presentation at the...

Facebook Twitter LinkedIn
Read more...
07AprApril 7, 2022

Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at Oxford Global’s 2021 Biomarkers UK Conference

Strattmont Group2022-04-11T11:45:35-04:00

Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at...

Facebook Twitter LinkedIn
Read more...
22MarMarch 22, 2022

Precision Biologics, Inc. Announces Issuance of U.S. Patent: “MONOCLONAL ANTIBODY NEO-201 FOR THE TREATMENT OF HUMAN CARCINOMAS”

Strattmont Group2022-04-11T11:43:49-04:00

Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announces that the U.S....

Facebook Twitter LinkedIn
Read more...
09MarMarch 9, 2022

Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics, San Diego, March 9, 2022

Strattmont Group2022-03-09T10:48:47-05:00

Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics 2022, San...

Facebook Twitter LinkedIn
Read more...
12…5Next  

Featured News

Dr. Philip M. Arlen gives keynote address on NEO-201 Developments at World Antibody Congress, San Diego, CA, March 20th, 2023
March 14, 2023
Precision Biologics Successfully Completes Safety Phase and Begins Enrollment in Phase 2 Trial Combining NEO-201 and Pembrolizumab (Keytruda)
December 14, 2022
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201
December 1, 2022
Want To Find Out More?

CONTACT INFO

301-500-8646

4814 Del Ray Avenue
Bethesda, MD 20814

COMPANY

Board
About Us
Contact Us
News and Events

CLINICAL

Pipeline
Diagnostics
Therapeutics
Clinical Trials

SCIENCE

Recent Publications
Publications – Historical
Abstracts
Posters
Presentations

© Copyright 2019-2022. Precision Biologics. All Rights Reserved.
Website Development By Strattmont Group